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Chronic demyelination is a hallmark of neurological disorders such as multiple sclerosis
(MS) and several leukodystrophies. In the central nervous system (CNS), remyelination is
a regenerative process that is often inadequate during these pathological states. In the
MS context, in situ evidence suggests that remyelination is mediated by populations
of oligodendrocyte progenitor cells (OPCs) that proliferate, migrate, and differentiate
into mature, myelin-producing oligodendrocytes at sites of demyelinated lesions. The
molecular programming of OPCs into mature oligodendrocytes is governed by a myriad
of complex intracellular signaling pathways that modulate this process. Recent research
has demonstrated the importance of specific and short non-coding RNAs, known as
microRNAs (miRNAs), in regulating OPC differentiation and remyelination. Fortunately, it
may be possible to take advantage of numerous developmental studies (both human
and rodent) that have previously characterized miRNA expression profiles from the early
neural progenitor cell to the late myelin-producing oligodendrocyte. Here we reviewmuch
of the work to date and discuss the impact of miRNAs on OPC and oligodendrocyte
biology. Additionally, we consider the potential for miRNA-mediated therapy in the context
of remyelination and brain repair.
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INTRODUCTION
Myelination of neurons is a critical process required for normal functioning of the adult
mammalian central nervous system (CNS). A loss of myelin (i.e., demyelination) is a pathological
hallmark in multiple sclerosis (MS) and several leukodystrophies, and significantly contributes
to the clinical manifestations of such diseases. Further understanding the cellular and molecular
mechanisms responsible for promoting and/or enhancing myelination within the CNS may
provide novel therapeutic avenues for those suffering from demyelinating disorders. While
several independent factors contribute to both the processes of developmental myelination and
remyelination in the CNS, many of these factors affect the highly regulated transition from
an immature proliferating oligodendrocyte progenitor cell (OPC) into a mature and functional
myelinating oligodendrocyte (OL). Over the past decade, one of themolecular mechanisms that has
received growing interest is the role of microRNAs (miRNAs), short non-coding RNA molecules,
during OL development and myelination (Barca-Mayo and Lu, 2012). Herein, we will review the
emerging function of miRNAs and their influences on CNSmyelin development and remyelination
during brain repair.
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Oligodendrocyte Development in the CNS
The ontogeny of OL development is complex and controlled by
multiple extrinsic and intrinsic mechanisms that promote the
progression from a pluripotent progenitor cell to an OL, many of
which are reviewed elsewhere (Miller, 2002; Emery, 2010; Gallo
and Deneen, 2014). Throughout this process, OPC proliferation
and differentiation are differentially regulated, with the cessation
in OPC proliferation being linked to OL differentiation and
maturation. This phenomenon is similar to those observed in a
variety of different post-mitotic cell types, however inhibiting cell
cycle progression is not sufficient to induce OL differentiation
(Casaccia-Bonnefil and Liu, 2003). Thus, the coordination of
multiple signaling pathways is needed for progenitor cells to
move from an immature state to a functional OL, a process that
is achieved in part by miRNAs.
miRNAs: Biogenesis and Function
miRNAs are endogenous, small non-coding RNA molecules,
typically 20–22 base pairs in length, and regulate gene expression
by binding to the 3′ untranslated region (UTR) of targetedmRNA
molecules. Through this process, miRNAs can regulate hundreds
of target genes and influence multiple pathways involved in
cellular development and homeostasis (Bartel, 2004;Winter et al.,
2009). Due to the critical roles of miRNAs, their production
and function is highly regulated within cells. The canonical
biogenesis pathway is initiated by the transcription of the primary
miRNA transcript, the pri-miRNA. This transcript is cleaved
within the nucleus by the Drosha-DGCR8 complex, thus forming
the precursor hairpin miRNA or pre-miRNA. The pre-miRNA is
transported into the cytoplasm via Exportin-5 - Ran-GTP nuclear
export. Within the cytoplasm the RNase enzyme Dicer1, along
with the RNA binding protein TRBP, then cleaves the pre-miRNA
to form the mature miRNA duplex consisting of both the -5p
and -3p mature miRNAs. Mature miRNAs associate with Ago2
protein to form the RNA-induced silencing complex (RISC),
which binds mRNA within the cytoplasm and ultimately leads
to cleavage, repression or deadenylation of the target mRNA.
Within the genome, many miRNAs aggregate within the same
pri-miRNA transcript, resulting in a miRNA family or cluster.
The clustering of miRNAs has functional significance and allows
multiple miRNAs with similar gene targets or function to be
transcribed simultaneously (Altuvia et al., 2005).
miRNAs As Emerging Regulators of CNS
Demyelination
Due to the broad actions of miRNAs in controlling multiple
systems (e.g., cell differentiation, apoptosis, inflammation,
homeostasis), it is unsurprising that miRNAs have emerged as
important molecules that regulate a variety of pathogenic
mechanisms in demyelinating diseases, including MS,
leukodystrophies, and perinatal hypoxia-ischemia. The most
well-characterized human demyelinating disease is MS, a chronic
inflammatory disease that affects the CNS. Although largely
immune-mediated, there is growing evidence suggesting primary
impairments in oligodendrocyte biology or an oligodendropathy
(Kutzelnigg et al., 2005; Trapp and Nave, 2008). miRNAs are
key regulators in MS pathology, as well as its animal model
experimental autoimmune encephalomyelitis (EAE), although
the primary focus has been on regulating the immune system.
Beyond the immune system, studies highlighting miRNAs as
key regulators of OPC differentiation and OL function may
have significant clinical implications with respect to further
understanding MS disease pathogenesis and identifying novel
drug targets that can promote brain repair. Within this review,
we will discuss several miRNAs that are specifically implicated
in oligodendrocyte biology and myelination, many of which are
altered in MS and other demyelinating diseases.
miRNAs AS KEY REGULATORS OF
OLIGODENDROCYTE DEVELOPMENT
Dicer1
Dicer is a critical miRNA-processing enzyme encoded by the
Dicer1 gene inmice and is required to generate functional mature
miRNAs from miRNA precursors. Mice lacking a functional
Dicer1 gene are embryonically lethal (Bernstein et al., 2003),
and as such, conditional knockouts are utilized to identify the
requirement and/or roles of miRNAs in specific cell lineages and
developmental studies. Approximately 70% of known miRNAs
are expressed in the brain (Cao et al., 2006), suggesting the
importance of miRNAs in the mammalian CNS. The role for
miRNAs during OL development and myelination was first
demonstrated in conditional knockouts lacking a functional
Dicer enzyme in mature oligodendrocytes expressing proteolipid
protein (PLP). This initial research led to the conclusion
that these mice experienced a substantial CNS impairment
(e.g., ataxia, paralysis) and did not survive beyond postnatal
month 14 (Shin et al., 2009). Further analysis of these mice
demonstrated reductions in several myelin proteins, including
myelin associated glycoprotein (MAG), myelin oligodendrocyte
protein (MOG), 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase
(CNPase) and PLP. The reduction in myelination was also
accompanied by axonal amyloid precursor protein deposition,
reduced axonal transport, increased oxidative stress, astrogliosis,
and microglial activation. As this cre/loxP model led to reduced,
albeit not abolished, Dicer1 expression in OLs, a microarray
analysis was performed using RNA isolated from whole brain.
When compared to wildtype mice, transgenic mice had reduced
expression of miR-32, -144, and -219, and upregulation of
miR-7a, -7b, -181a-1, and -592. Following this initial finding,
two concurrent reports demonstrated the necessity of miRNAs
through conditional knockout of Dicer1 in earlier OPC lineage
cells (e.g., Olig1, Olig2, CNP) on OL development (Dugas et al.,
2010; Zhao et al., 2010). Olig1 and Olig2 are highly expressed
within OPCs, while CNP expression is highest during the
differentiation of immature OLs (Zhou et al., 2000; Baumann
and Pham-Dinh, 2001). All OL lineage conditional knockout
mice presented a “shiverer” mouse-like (MBP KO) phenotype
in early postnatal days, while Olig1 and CNP targeted deletion
led to mortality within 1 month. Interestingly, Olig2 floxed mice
survived, eventually generated normal appearing myelin, and
were indistinguishable from wildtype littermate controls. Within
the first postnatal month, all knockout mice showed reduced
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myelination, however, changes in axonal survival were not seen.
Subsequent in vivo and in vitro studies using CNP and Olig1
targeted Dicer1 knockout mice demonstrated increased numbers
of progenitor cells, suggesting a failure of OPCs to differentiate
into mature OLs, and presents further evidence that miRNAs
are indispensable for the transition from progenitor cell to
myelinating OL.
miR-219, -338, -138
An analysis of miRNA profiles in normal CNS development
and Dicer1 knockout models has identified miR-219 as a
critical miRNA involved in oligodendrocyte development (Shin
et al., 2009; Dugas et al., 2010; Zhao et al., 2010) and has
become a highly studied miRNA in the context of myelin
biology. Microarray analysis of GalC+A2B5− oligodendrocytes
vs. A2B5+GalC− neuronal progenitor cells identified elevated
miR-219 expression in mature oligodendrocytes (Lau et al.,
2008). Later reports show that miR-219 is a potent inducer of
OL differentiation, while exogenous administration of miR-219
rescues deficits in myelination seen in Dicer1 knockouts both
in vitro and in vivo (Dugas et al., 2010; Zhao et al., 2010).
The mechanism of action of miR-219 has been attributed to
repressing factors that inhibit oligodendrocyte differentiation,
including Sox6, Hes5, Foxj3, Pdgfr-α, and Zfp238. miR-219
expression remains elevated following differentiation to OL
(Figure 1). The functional significance of elevated miR-219
expression has been attributed to the repression of Elovl7, a
fatty acid elongation factor that can result in lipid accumulation
and neurodegeneration when overexpressed (Shin et al., 2009).
miR-219 expression is also upregulated during human OPC
differentiation and correlates with the expression of PLP in
human samples (de Faria et al., 2012). Within the adult human
brain, miR-219 is highly expressed in OLs, with reduced but
detectable expression in human A2B5+ and O4+ progenitors
(Leong et al., 2014). Thus, miR-219 is not only important for
the transition of OPC to OL, but may also be important in the
formation and maintenance of myelin.
In addition to miR-219, miR-338 is also upregulated in mature
vs. immature oligodendrocytes (Lau et al., 2008). miR-338 is
highly expressed in the spinal cord and optic nerve, where it
overlaps with oligodendrocyte markers CC1 and Olig2 (Zhao
et al., 2010). Inhibition of miR-338 blocks oligodendrocyte
maturation in vitro, while elevated miR-388 increases OL
differentiation (Zhao et al., 2010). miR-338 also controls the
differentiation of OPCs into mature oligodendrocytes through
the inhibition of oligodendrocyte differentiation inhibitors,
notably Hes5 and Sox6 (Zhao et al., 2010). Using in silico
analysis, both miR-338 and miR-219 are predicted to target other
genes including NeuroD1, Isl1, and Otx2, which are inhibitors
of the transition from neural stem cell to OPC (Lee et al.,
1995; Pfaff et al., 1996; Vernay et al., 2005; Zhao et al., 2010).
In humans, miR-338 is upregulated during differentiation of
humanOPCs (de Faria et al., 2012). Furthermore, miR-338 is also
present in neurons and targets enzymes involved in neurosteroid
production (ARK1C1 and ARK1C2; Noorbakhsh et al., 2011), a
finding that suggests additional roles for miR-338 in neural cell
development beyond the OL lineage.
miR-138 is an additional miRNA with higher expression in
mature oligodendrocytes compared with OPCs (Dugas et al.,
2010). miR-138 expression is increased in both CNS white matter
and oligodendrocytes, and has low expression in neurons and
astrocytes. Notably, miR-138 is not as potent as other OL-
promoting miRNAs such as miR-219 and miR-338 (Dugas et al.,
2010). In vitro,miR-138 induced oligodendrocyte differentiation
and expression of CNP and MBP. Additionally, miR-138 targets
the Sox4 transcription factor, a repressor of OL maturation
(Potzner et al., 2007; Yeh et al., 2013). In contrast, sustained
expression of miR-138 eventually leads to reductions in MOG
protein, suggesting miR-138 may have a transient role in OPC
differentiation and a Janus role in the transition to a mature OL.
Strikingly, miR-219 and -338 are two of the most highly
downregulated miRNAs in chronic MS lesions (Junker et al.,
2009). Due to the critical role of miR-219 and -338 in
oligodendrocyte differentiation, this finding suggests a failure of
OPCs to differentiate into mature OLs in chronic MS lesions.
It is also possible that reductions in levels of these miRNAs are
simply due to reductions in OLs, as these miRNAs are highly
expressed inmature OLs; single cell laser capturemicrodissection
(LCM) may help to resolve this issue. Further studies comparing
miRNA profiles of MS patient white matter to healthy control
tissue has demonstrated an upregulation in miR-219 and -
338 in MS patients (Noorbakhsh et al., 2011), suggesting an
ongoing remyelination process in the MS brain. Demyelinated
hippocampal sections of MS patients display reductions miR-138
expression (Dutta et al., 2013). These initial studies offer a gross
examination of miRNA dysregulation in MS lesions, however
further identification of miRNAs that have differential expression
in cells of OL lineage within pathological states is still needed.
Perinatal hypoxia-ischemia (HI) in pre-term babies often
results in white matter injury due to OPC susceptibility. Perinatal
HI results in increased OPCs accompanied by reductions in
mature OLs, suggesting a block in the transition fromOPC toOL.
The role of miRNAs in HI was investigated utilizing NG2 specific
Dicer1 KO mice. This model demonstrated that a loss of Dicer1
in OPCs increased numbers of mature OLs and MBP expression
in a murine model of HI (Birch et al., 2014). This increase
in myelination was coupled with a recovery in murine motor
performance. Furthermore, miRNA profiling in this murine
model at multiple time points demonstrated increases in miR-
138, -338, and -21 following HI (Birch et al., 2014). These results
are unexpected due to impaired remyelination seen in Dicer1
KO mice, along with the increases of miR-138 and -338 in OPC
differentiation, an impaired process in HI. Further studies are
needed to reconcile the roles of miRNAs in this disorder.
miR-23a
miR-23a was initially identified as a regulator of lamin B1,
an inhibitor of myelin gene expression (Lin and Fu, 2009).
miR-23a directly represses lamin B1 and is inversely correlated
with lamin B1 expression in mouse brain tissue; increased
miR-23a expression promotes CNP and MBP expression in
mixed glial cultures (Lin and Fu, 2009). Further work by this
group has utilized CNP specific overexpression of miR-23a to
assess the role of miR-23a in myelination (Lin et al., 2013)
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FIGURE 1 | miRNAs Implicated in OL Differentiation. Several miRNAs have been demonstrated to influence the development from a self-renewing neural stem
cell (NSC) to a mature, myelinating oligodendrocyte. As OLs differentiate, the expression of multiple miRNAs including miR-9, -23a, -138, -219, -338, and -297c
increases and affects the process of differentiation through the repression of target gene mRNA. miRNAs that promote OL differentiation do so by inhibiting repressors
of OL differentiation such as Hes5, Sox6, Ccnt2, and Foxj3 or by inhibiting genes that promote the proliferation of NSCs and OPCs such as Fgfr2 and pdgfrα. miRNAs
may also exert effects through the suppression of inappropriate genes, as is the case for miR-9 suppressing Pmp22.
and demonstrated that OL specific overexpression of miR-
23a results in significant hind-limb paralysis, loss of extensor
tone and kyphosis compared to wildtype controls. The motor
deficits observed in the miR-23a conditional knockout mice
were accompanied by hypermyelination (which can also result
in severe motor impairment) and increases in Luxol fast blue
staining, as well as increased CNP, MBP, and MAG protein
expression. Axons within the transgenic mice also demonstrated
increases in myelin diameter observed by electron microscopy
compared to controls. The in vivo changes in myelination
were further corroborated by increases in OL cell number and
myelin gene expression in vitro. The mechanism of action that
underlies the phenotypic changes associated with increased miR-
23a expression were linked to repression of the Pten gene, a
known regulator of myelination that acts to inhibit Akt-signaling
and growth factor signaling such as IGF-1 (Harrington et al.,
2010; De Paula et al., 2014). Additionally, a long non-coding RNA
(2700046G09Rik) was also identified as a novel regulator of OL
development and is a bona fidemiR-23a regulated gene (Lin et al.,
2013).
Pathological studies of miRNA expression within the MS
brain have compared miRNAs in both acute and chronic lesions,
and the normal appearing white matter (NAWM; Junker et al.,
2009). miRNA analysis of MS patient brain tissue demonstrated
increases in miR-23a within active MS lesions. Furthermore,
expression levels of miR-23a were dramatically increased in
chronic lesions. miR-23a levels are also elevated in the spinal
cords of EAE mice and non-human primates (Lescher et al.,
2012). An interesting genetic analysis has demonstrated increases
in the frequency of the miR-23a allele 3745453 have been
identified as a risk factor in MS (Ridolfi et al., 2013). Increased
miR-23a, a myelin promoting miRNA, in MS brain tissue may be
the result of the ongoing remyelination process in MS, however,
MS patient peripheral immune cells also demonstrate increased
miR-23a expression (Ridolfi et al., 2013). Thus, the increases in
miR-23a within the MS brain may be a byproduct of increased
immune cell infiltration.
Leukodystrophies are diseases that display prominent loss
of myelin in the absence of axonal loss and inflammation.
Autosomal dominant leukodystrophy (ADLD) has been
attributed to mutations in the Lmnb1 gene that result in
increased Lmnb1 expression and myelin gene repression. As
previously mentioned, miR-23a has been identified as a bona
fide regulator of Lmnb1; increases in miR-23a can rescue deficits
generated by Lmnb1 overexpression in vitro (Lin and Fu, 2009).
Further reports utilizing in vivo ADLD mouse models and
patient samples are needed to further assess the role of miR-23a
in this disease.
miR-17-92 Cluster
Analysis of miRNA expression patterns in cells along the OL
lineage has demonstrated that several members of the miR-17-
92 cluster are preferentially upregulated in OLs. Conditional
deletion of the miR-17-92 cluster in CNP-expressing OLs
diminished numbers of Olig2+ OLs. Furthermore, the addition
of miR-17-92 cluster pre-miRNA leads to increased numbers
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of OLs in vitro; knockdown of pre-miR-17-92 decreased OL
numbers (Budde et al., 2010). These changes were associated
with regulation of Pten (Harrington et al., 2010), a regulator
of OPC differentiation mentioned previously. The miR-17-92
cluster is also enriched in human white matter, suggesting that
this cluster performs similar functions in the development of
human oligodendrocytes. Despite this enrichment, the miR-17-
92 cluster has reduced expression during the differentiation of
rodent OPCs, a finding not replicated in human progenitor cells
(de Faria et al., 2012).
Sfmbt2 Cluster
The Sfmbt2 cluster is a cluster of miRNAs named after
their distribution along the Sfmbt2 gene, is expressed within
embryonic stem cells, and impacts embryonic development
(Zheng et al., 2011). This cluster of miRNAs has been recently
identified as a regulator of oligodendrocyte development and
remyelination during cuprizone-induced demyelination
(Kuypers et al., 2016). Using the cuprizone model of
demyelination (and subsequent remyelination), the authors used
CNPase-eGFP reporter mice to identify cells of oligodendrocyte
lineage. eGFP expressing cells were sorted from the corpus
callosum of mice at multiple time points throughout the
experimental timeline, and 38 miRNAs, including members of
the Sfmbt2 family, were downregulated during demyelination
and subsequently increased during remyelination. Further
analysis identified one miRNA, miR-297c-5p, as highly
upregulated during oligodendrocyte differentiation. The
functional significance of miR-297c-5p upregulation was
attributed to the gene target Cyclin T2 (Ccnt2), a regulator of cell
cycle progression and a negative regulator of OPC differentiation
(Kim et al., 2012; Kuypers et al., 2016).
Other miRNAs
miR-9 plays a critical role in the maturation of oligodendrocytes
and Schwann cells by repressing PMP-22, a peripheral myelin
protein (Adlkofer et al., 1995). miR-9 is enriched within OPCs
of the CNS, but absent within the PNS, an expression pattern
reciprocal with PMP-22 expression in these two compartments
(Lau et al., 2008). Interestingly, PMP-22 mRNA is present
within the CNS, however, its protein expression is absent (Dugas
et al., 2006). These observations suggest that miR-9 may have
additional roles in myelination of the CNS through the silencing
of PNS myelin genes that would otherwise be inappropriately
expressed within the CNS (Lau et al., 2008; Dugas and Notterpek,
2011); in the PNS, low levels of mir-9 may help to promote
myelination by Schwann cells. When comparing miRNA levels in
the MS brain, miR-9 is highly upregulated in chronic lesions vs.
NAWM (Junker et al., 2009), however miR-9 levels are decreased
compared to white matter fromMS samples and healthy controls
(Noorbakhsh et al., 2011).
miR-124 is highly expressed in mature neurons and influences
the differentiation of progenitor cells to neurons. Despite its
restricted expression in neurons, and not oligodendrocytes,
miR-124 is increased during hippocampal demyelination in
both human MS samples and mice undergoing cuprizone-
induced demyelination (Dutta et al., 2013). miR-124 was also
demonstrated to target AMPA receptor mRNA and potentially
modulate learning and memory through this mechanism. This
finding adds further complexity to the roles of miRNAs in
myelin biology, as demyelination results in altered neural
miRNA expression and subsequent function as a result of
miRNA dysregulation. Furthermore, loss of miR-124 in zebrafish
development resulted in reduced MBP+ cell numbers, likely due
to the indirect influence of miR-124 on neurons and disruption
of axonal-glial signals and cross-talk that are required for proper
OL maturation and myelination (Morris et al., 2015).
Investigating the expression of miRNAs involved in OPC
differentiation in vitro utilizing human embryonic stem cells
has uncovered a handful of miRNAs that may be important
in OL development. Validated miRNAs from this study include
miR-199a-5p, -145, -214-, -184, and -1183 (Letzen et al.,
2010). Predicted targets of these miRNAs include a variety of
myelin-associated proteins, and specifically miR-214 is a likely
regulator of myelin-associated oligodendrocyte basic protein that
correlates with decreased expression of miR-214 during OPC
development in primary human OPCs and embryonic stem cell
derived progenitors (Letzen et al., 2010; Leong et al., 2014). miR-
214 is also elevated in active and chronic MS lesions, potentially
as a result of the ongoing remyelination process (Junker et al.,
2009).
mir-146a is a well-characterized mediator of the innate
immune response by targeting the TRAF6 and IRAK1 genes
(Taganov et al., 2006). Using in vitro cultures of OPCs, the
transfection of mature miR-146a promotes the differentiation
of MBP expressing OLs from OPCs (Santra et al., 2014; Liu
et al., 2016). In situ analysis using a rat model of stroke also
identified increased miR-146a in the post-stroke brain. Increased
expression of miR-146a was sufficient to increase the number of
MBP+ OLs in an in vitro OPC culture system (Liu et al., 2016).
miRNAs within the miR-181 family have been identified
as miRNAs with possible roles in OL biology. Specifically,
miR-181a-1 is upregulated in the brains of mice lacking
functional Dicer within PLP expressing OLs (Shin et al., 2009)
while miR-181a, -181a∗, -181c, and -181d were increased in
OLs compared to OPCs (Dugas et al., 2010). miR-181a is
additionally upregulated in isolated human fetal OPCs and
adult OLs, however, expression is reduced in adult human
OPCs and neural progenitors (Leong et al., 2014). The miR-
181 family has previously been implicated in CNS ischemia
and inflammation (Hutchison et al., 2013; Moon et al., 2013),
although a functional role for this miRNA in OL differentiation
has not yet been established. Interestingly, miR-181c has been
implicated as a potential MS biomarker and is downregulated
in the cerebrospinal fluid (CSF) of MS patients (Haghikia et al.,
2012).
miRNAs AS POTENTIAL BIOMARKERS
AND THERAPEUTIC TARGETS
miRNA expression patterns have been extensively studied as
potential biomarkers in demyelinating diseases such as MS. With
respect to inflammation and immune cell activity, potential
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miRNA biomarkers have been assessed in the peripheral
compartment and include the miR-145 and -155 (Keller et al.,
2009; Moore et al., 2013). Of interest to myelin biology, miR-
92a-1, a member of the miR-17-92 cluster, has been identified
as a potential biomarker in serum that is not only associated
with MS patient disease severity and duration, but is also
elevated in secondary progressive vs. relapsing MS (Gandhi et al.,
2013). Serum levels of miR-23a are also downregulated in MS
patients with primary progressive MS, a result that correlates
with disability score (Fenoglio et al., 2013). The ability to identify
decreases in myelin promoting miRNAs in the serum of patients
undergoing progressive demyelination (a finding that correlated
with disease score) may point to deficits in remyelination and the
miRNAs underlying this process.
Beyond biomarkers, there has been an increasing interest
in utilizing miRNAs as therapeutic targets in many disease
states, including demyelinating diseases. The production of novel
miRNA therapeutics typically seeks to either antagonize specific
miRNAs that contribute to pathology, an approach taken with
miR-122 in the course of Hepatitis C (Lanford et al., 2010),
or administer exogenous miRNAs that promote resolution and
repair. In the context of myelination and myelin repair, miR-
219 has emerged as a potential target to enhance myelination.
It has been demonstrated that exposure of aging animals to
a youthful milieu is beneficial in promoting remyelination
(Ruckh et al., 2012; Miron et al., 2013). Work by the Kraig
laboratory has demonstrated that youthful rats and rats exposed
to environmental enrichment generate serum exosomes that
promote remyelination both in vitro utilizing lysolecithin treated
slice cultures and in vivo following nasal administration of
exosomes to aged rats (Pusic and Kraig, 2014). This effect was
attributed to the presence of functional miR-219 within the
exosomes, which was able to repress its target genes NeuroD1,
Pdgfr-α, and Elovl7. Furthermore, IFNγ-stimulated dendritic
cells were also shown to generate exosomes containing miR-219,
which subsequently improved remyelination (Pusic et al., 2014).
DISCUSSION AND PERSPECTIVES
miRNAs have emerged as indispensable regulators ofmyelination
of the CNS. Recent studies have characterized the roles of
many key miRNA molecules that are central in this process
and the mechanisms though which they exude their effect.
However, several major areas of research still need to be
addressed. First, although many of these molecules have
been assessed in the context of development, research into
the roles miRNAs perform in the remyelination process is
needed. Secondly, the expression and possible dysregulation
of miRNAs within the OL compartment must be assessed
in the context of the pathological brain. Can we identify
altered miRNA expression in OLs of individuals suffering
from demyelinating disorder? Are there perhaps novel miRNA
regulators that govern remyelination in the adult CNS?
The use of in vitro and in vivo models of remyelination
will be key in answering these questions. As miRNAs
continue to move from the bench and into clinical trials,
the possibility for miRNAs to prevent demyelination and
promote remyelination represents a promising area in research
and medicine.
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